 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc., Nasdaq: STOK, a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy Pain Specialty Therapeutics Conference on Thursday, December 10, 2020, at 12:45 p.m. ET. A live audio webcast of the fireside 